ArticleBlood advances2026

Cost comparison of pdVWF/FVIII prophylaxis and on-demand therapy in type 3 von Willebrand disease in the United States.

Robert F Sidonio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.